Gene expression analysis in predicting the effectiveness of insect venom immunotherapy
Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available. To determ...
Saved in:
| Published in | Journal of allergy and clinical immunology Vol. 125; no. 5; pp. 1092 - 1097 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York, NY
Mosby, Inc
01.05.2010
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available.
To determine the use of gene expression profiles to predict the long-term effect of VIT.
Whole genome gene expression analysis was performed on RNA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT.
Among the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression (
P < .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT.
Gene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance. |
|---|---|
| AbstractList | Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available.
To determine the use of gene expression profiles to predict the long-term effect of VIT.
Whole genome gene expression analysis was performed on RNA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT.
Among the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression (
P < .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT.
Gene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance. Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available. Objective - To determine the use of gene expression profiles to predict the long-term effect of VIT. Methods - Whole genome gene expression analysis was performed onA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT. Results - Among the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression (P < .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT. Conclusion - Gene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance. Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available.BACKGROUNDVenom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available.To determine the use of gene expression profiles to predict the long-term effect of VIT.OBJECTIVETo determine the use of gene expression profiles to predict the long-term effect of VIT.Whole genome gene expression analysis was performed on RNA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT.METHODSWhole genome gene expression analysis was performed on RNA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT.Among the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression (P < .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT.RESULTSAmong the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression (P < .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT.Gene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance.CONCLUSIONGene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance. Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available. To determine the use of gene expression profiles to predict the long-term effect of VIT. Whole genome gene expression analysis was performed on RNA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT. Among the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression (P < .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT. Gene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance. Background Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available. Objective To determine the use of gene expression profiles to predict the long-term effect of VIT. Methods Whole genome gene expression analysis was performed on RNA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT. Results Among the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression (P< .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT. Conclusion Gene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance. Background Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction increases after completion of treatment. No reliable factors predicting individual lack of efficacy of VIT are currently available. Objective To determine the use of gene expression profiles to predict the long-term effect of VIT. Methods Whole genome gene expression analysis was performed on RNA samples from 46 patients treated with VIT divided into 3 groups: (1) patients who achieved and maintained long-term protection after VIT, (2) patients in whom insect venom allergy relapsed, and (3) patients still in the maintenance phase of VIT. Results Among the 48.071 transcripts analyzed, 1401 showed a >2 fold difference in gene expression ( P < .05); 658 genes (47%) were upregulated and 743 (53%) downregulated. Forty-three transcripts still show significant differences in expression after correction for multiple testing; 12 of 43 genes (28%) were upregulated and 31 of 43 genes (72%) downregulated. A naive Bayes prediction model demonstrated a gene expression pattern characteristic of effective VIT that was present in all patients with successful VIT but absent in all subjects with failure of VIT. The same gene expression profile was present in 88% of patients in the maintenance phase of VIT. Conclusion Gene expression profiling might be a useful tool to assess the long-term effectiveness of VIT. The analysis of differently expressed genes confirms the involvement of immunologic pathways described previously but also indicates novel factors that might be relevant for allergen tolerance. |
| Author | Wijmenga, Cisca Niedoszytko, Marek de Monchy, Jan Platteel, Mathieu Jassem, Ewa Oude Elberink, Joanne N.G. Bruinenberg, Marcel |
| Author_xml | – sequence: 1 givenname: Marek surname: Niedoszytko fullname: Niedoszytko, Marek email: mnied@amg.gda.pl organization: Department of Allergology, Medical University of Gdansk, Gdansk, Poland – sequence: 2 givenname: Marcel surname: Bruinenberg fullname: Bruinenberg, Marcel organization: Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands – sequence: 3 givenname: Jan surname: de Monchy fullname: de Monchy, Jan organization: Department of Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands – sequence: 4 givenname: Cisca surname: Wijmenga fullname: Wijmenga, Cisca organization: Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands – sequence: 5 givenname: Mathieu surname: Platteel fullname: Platteel, Mathieu organization: Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands – sequence: 6 givenname: Ewa surname: Jassem fullname: Jassem, Ewa organization: Department of Allergology, Medical University of Gdansk, Gdansk, Poland – sequence: 7 givenname: Joanne N.G. surname: Oude Elberink fullname: Oude Elberink, Joanne N.G. organization: Department of Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22823937$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20334904$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkt-K1DAUxoOsuLOjL-CFFES86pg_TZuICLLoKix4oeJlyKQnmtqms0lncd7GZ_HJPGVGFwbcvQo5_L4v5PvOGTmJYwRCHjO6YpTVL7pVZ11YcYoDylaUs3tkwahuylpxeUIWlGpW1k2lT8lZzh3Fu1D6ATnlVIhK02pBvl5AhAJ-bhLkHMZY2Gj7XQ65CLHAYRvcFOK3YvqOlPeAt2tU5FyM_vevEDNOCpyMQxGGYRtHBJPd7B6S-972GR4dziX58u7t5_P35eXHiw_nby5LJ7WcSuWtbKlqGyW9V7WTDZNOWN5IQVtH141ee1Ci4rBugVZeMsYsgBTSa6prLZbk-d53k8arLeTJDCE76HsbYdxm08hK1apGvztJIQRlXAoknx6R3bhNmEs2TErKNKsxwCV5cqC26wFas0lhsGln_maLwLMDYLOzvU82upBvOK640KJBju85l8acE_h_CKNmLtp0Zi7azEUbygwWjSJ1JHJhshM2OCUb-tulr_ZSwF6uAySTXYDosOuEbZp2DLfLXx_JXR9iwB_-gB3km6hM5oaaT_MSzjvIcP0YkzUavPy_wV2v_wELtOs0 |
| CODEN | JACIBY |
| CitedBy_id | crossref_primary_10_1080_08820139_2019_1617303 crossref_primary_10_1111_all_16132 crossref_primary_10_1111_j_1398_9995_2010_02521_x crossref_primary_10_1016_j_jaci_2011_01_027 crossref_primary_10_1159_000447637 crossref_primary_10_1016_j_jaci_2010_11_024 crossref_primary_10_1002_jgm_3243 crossref_primary_10_1111_j_1398_9995_2012_02817_x crossref_primary_10_1016_j_jaci_2014_06_032 crossref_primary_10_1016_j_anai_2011_01_007 crossref_primary_10_1159_000365215 crossref_primary_10_3390_ijms25063499 crossref_primary_10_1186_2045_7022_3_35 crossref_primary_10_1016_j_imlet_2018_10_005 |
| Cites_doi | 10.1067/mai.2001.119154 10.1186/gb-2007-8-1-r3 10.1016/j.jaci.2006.04.040 10.1016/S0091-6749(00)90092-7 10.1371/journal.pbio.0060316 10.1371/journal.pmed.1000024 10.1016/S0091-6749(97)70314-2 10.1093/nar/gkm882 10.3109/02770906609106941 10.1016/j.jaci.2007.05.001 10.1093/nar/gkj102 10.1016/j.jaci.2005.01.055 10.1074/jbc.M801531200 10.1038/sj.jid.5700882 10.1214/aos/1013699998 10.1016/S0166-4328(01)00297-2 10.1111/j.1398-9995.2005.00960.x 10.1111/j.1398-9995.2006.01175.x 10.1016/j.radonc.2007.10.019 10.1034/j.1399-3038.2003.00025.x 10.1016/S0933-3657(01)00077-X 10.1016/S0091-6749(98)70167-8 10.1093/nar/gkp416 10.1136/gut.2003.018374 |
| ContentType | Journal Article |
| Copyright | 2010 American Academy of Allergy, Asthma & Immunology American Academy of Allergy, Asthma & Immunology 2015 INIST-CNRS Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved. Copyright Elsevier Limited May 2010 Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved. |
| Copyright_xml | – notice: 2010 American Academy of Allergy, Asthma & Immunology – notice: American Academy of Allergy, Asthma & Immunology – notice: 2015 INIST-CNRS – notice: Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved. – notice: Copyright Elsevier Limited May 2010 – notice: Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7SS 7T5 H94 K9. NAPCQ 7X8 |
| DOI | 10.1016/j.jaci.2010.01.021 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Entomology Abstracts (Full archive) Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Entomology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE Entomology Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-6825 |
| EndPage | 1097 |
| ExternalDocumentID | 3389957141 20334904 22823937 10_1016_j_jaci_2010_01_021 S0091674910001156 1_s2_0_S0091674910001156 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Polish Ministry of Science and Higher Education grantid: N402085934 – fundername: ALK-Abelló and Novartis |
| GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .XZ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 354 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8F7 8FE 8FH 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABJNI ABLJU ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN ADXHL AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BPHCQ BVXVI C45 CAG CJTIS COF CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDU HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B LK8 LUGTX M27 M41 MO0 N4W N9A O-L O9- O9~ OAUVE OBH ODZKP OHH OHT OK0 OK1 OVD OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SJN SPCBC SSH SSI SSZ T5K TEORI TWZ UGJ UNMZH UV1 WH7 WOW WUQ X7M XFW YOC YQI YQJ Z5R ZGI ZXP ZY1 ~02 ~G- ~KM AACTN RIG AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7SS 7T5 H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c595t-8fa5d08d785ff86c5715c3a27530dc0b79bfe8342ebde04f5111aee535f909693 |
| IEDL.DBID | .~1 |
| ISSN | 0091-6749 1097-6825 |
| IngestDate | Fri Jul 11 07:59:46 EDT 2025 Thu Jul 10 22:46:29 EDT 2025 Wed Aug 13 08:02:23 EDT 2025 Thu Apr 03 06:57:04 EDT 2025 Mon Jul 21 09:16:34 EDT 2025 Tue Jul 01 04:31:58 EDT 2025 Thu Apr 24 23:10:02 EDT 2025 Sun Apr 06 06:54:17 EDT 2025 Wed Apr 02 07:27:49 EDT 2025 Tue Aug 26 16:36:31 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | VIT Insect venom allergy TWIST2 microarray assessment SNX33 MAPK CLDN1 PRLR STAT IVA venom immunotherapy gene expression prediction of treatment efficacy SLC16A4 Claudin 1 Signal transducer and activator of transcription sh3 and px domain containing 3 Mitogen-activated protein kinase Solute carrier family 16 Transcription factor twist homolog 2 Prolactin receptor Allergy Immunopathology Treatment efficiency Insecta Prediction Gene expression Immunology Treatment Arthropoda Immunotherapy Venom Invertebrata Predictive factor |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c595t-8fa5d08d785ff86c5715c3a27530dc0b79bfe8342ebde04f5111aee535f909693 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://www.jacionline.org/article/S0091674910001156/pdf |
| PMID | 20334904 |
| PQID | 1550191620 |
| PQPubID | 105664 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_754868675 proquest_miscellaneous_733301253 proquest_journals_1550191620 pubmed_primary_20334904 pascalfrancis_primary_22823937 crossref_primary_10_1016_j_jaci_2010_01_021 crossref_citationtrail_10_1016_j_jaci_2010_01_021 elsevier_sciencedirect_doi_10_1016_j_jaci_2010_01_021 elsevier_clinicalkeyesjournals_1_s2_0_S0091674910001156 elsevier_clinicalkey_doi_10_1016_j_jaci_2010_01_021 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2010-05-01 |
| PublicationDateYYYYMMDD | 2010-05-01 |
| PublicationDate_xml | – month: 05 year: 2010 text: 2010-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States – name: St. Louis |
| PublicationTitle | Journal of allergy and clinical immunology |
| PublicationTitleAlternate | J Allergy Clin Immunol |
| PublicationYear | 2010 |
| Publisher | Mosby, Inc Elsevier Elsevier Limited |
| Publisher_xml | – name: Mosby, Inc – name: Elsevier – name: Elsevier Limited |
| References | Kanehisa, Goto, Hattori, Aoki-Kinoshita, Itoh, Kawashima (bib15) 2006; 34 Schöbel, Neumann, Hertweck, Dislich, Kuhn, Kremmer (bib26) 2008; 283 Simons, Frew, Ansotegui, Bochner, Golden, Finkelman (bib7) 2007; 120 Kanehisa, Araki, Goto, Hattori, Hirakawa, Itoh (bib14) 2008; 36 Sharabi, Aldrich, Sosic, Olson, Friedman, Lee (bib13) 2008; 6 Jutel, Akdis, Blaser, Akdis (bib18) 2006; 61 Golden, Kagey-Sobotka, Lichtenstein (bib2) 2000; 105 Crijns, Fehrmann, de Jong, Gerbens, Meersma, Klip (bib22) 2009; 6 Mueller (bib10) 1966; 3 Lerch, Müller (bib4) 1998; 101 Kononenko (bib9) 2001; 23 Konno, Golden, Schroeder, Hamilton, Lichtenstein, Huang (bib20) 2005; 115 Nogales-Cadenas, Carmona-Saez, Vazquez, Vicente, Yang, Tirado (bib16) 2009; 37 Ippoliti, De Santis, Volterrani, Lenti, Canitano, Lucarelli (bib23) 2003; 14 Zimmerli, Hauser (bib24) 2007; 127 Liu, Xavier, Good, Chtanova, Newton, Sisavanh (bib19) 2006; 118 Kazmierska, Malicki (bib8) 2008; 86 Golden (bib1) 2003; 67 Carmona-Saez, Chagoyen, Tirado, Carazo, Pascual-Montano (bib17) 2007; 8 COMMD8 gene function. Available at SLC16A4 gene function. Available at . Oude Elberink, de Monchy, Kors, van Doormaal, Dubois (bib6) 1997; 99 Diosdado, Wapenaar, Franke, Duran, Goerres, Hadithi (bib21) 2004; 53 Benjamini, Drai, Elmer, Kafkafi, Golani (bib12) 2001; 125 Ruëff, Wenderoth, Przybilla (bib5) 2001; 108 Bonifazi (bib3) 2005; 60 Benjamini, Yekutieli (bib11) 2001; 29 Bonifazi (10.1016/j.jaci.2010.01.021_bib3) 2005; 60 Mueller (10.1016/j.jaci.2010.01.021_bib10) 1966; 3 Schöbel (10.1016/j.jaci.2010.01.021_bib26) 2008; 283 Kazmierska (10.1016/j.jaci.2010.01.021_bib8) 2008; 86 Lerch (10.1016/j.jaci.2010.01.021_bib4) 1998; 101 Ruëff (10.1016/j.jaci.2010.01.021_bib5) 2001; 108 Zimmerli (10.1016/j.jaci.2010.01.021_bib24) 2007; 127 Jutel (10.1016/j.jaci.2010.01.021_bib18) 2006; 61 Liu (10.1016/j.jaci.2010.01.021_bib19) 2006; 118 Golden (10.1016/j.jaci.2010.01.021_bib1) 2003; 67 Carmona-Saez (10.1016/j.jaci.2010.01.021_bib17) 2007; 8 Ippoliti (10.1016/j.jaci.2010.01.021_bib23) 2003; 14 Golden (10.1016/j.jaci.2010.01.021_bib2) 2000; 105 Kononenko (10.1016/j.jaci.2010.01.021_bib9) 2001; 23 Kanehisa (10.1016/j.jaci.2010.01.021_bib14) 2008; 36 Kanehisa (10.1016/j.jaci.2010.01.021_bib15) 2006; 34 Nogales-Cadenas (10.1016/j.jaci.2010.01.021_bib16) 2009; 37 Diosdado (10.1016/j.jaci.2010.01.021_bib21) 2004; 53 10.1016/j.jaci.2010.01.021_bib27 Oude Elberink (10.1016/j.jaci.2010.01.021_bib6) 1997; 99 Crijns (10.1016/j.jaci.2010.01.021_bib22) 2009; 6 10.1016/j.jaci.2010.01.021_bib25 Konno (10.1016/j.jaci.2010.01.021_bib20) 2005; 115 Simons (10.1016/j.jaci.2010.01.021_bib7) 2007; 120 Sharabi (10.1016/j.jaci.2010.01.021_bib13) 2008; 6 Benjamini (10.1016/j.jaci.2010.01.021_bib11) 2001; 29 Benjamini (10.1016/j.jaci.2010.01.021_bib12) 2001; 125 |
| References_xml | – volume: 86 start-page: 211 year: 2008 end-page: 216 ident: bib8 article-title: Application of the naïve Bayesian classifier to optimize treatment decisions publication-title: Radiother Oncol – volume: 34 start-page: 354 year: 2006 end-page: 357 ident: bib15 article-title: From genomics to chemical genomics: new developments in KEGG publication-title: Nucleic Acids Res – volume: 23 start-page: 89 year: 2001 end-page: 109 ident: bib9 article-title: Machine learning for medical diagnosis: history, state of the art and perspective publication-title: Artif Intell Med – volume: 53 start-page: 944 year: 2004 end-page: 951 ident: bib21 article-title: A microarray screen for novel candidate genes in coeliac disease pathogenesis publication-title: Gut – volume: 67 start-page: 2541 year: 2003 end-page: 2546 ident: bib1 article-title: Stinging insect allergy publication-title: Am Fam Physician – volume: 101 start-page: 606 year: 1998 end-page: 612 ident: bib4 article-title: Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients publication-title: J Allergy Clin Immunol – volume: 61 start-page: 796 year: 2006 end-page: 807 ident: bib18 article-title: Mechanisms of allergen specific immunotherapy—T-cell tolerance and more publication-title: Allergy – volume: 99 start-page: 153 year: 1997 end-page: 154 ident: bib6 article-title: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis publication-title: J Allergy Clin Immunol – volume: 120 start-page: 2 year: 2007 end-page: 24 ident: bib7 article-title: Risk assessment in anaphylaxis: current and future approaches publication-title: J Allergy Clin Immunol – volume: 6 start-page: e316 year: 2008 ident: bib13 article-title: Twist-2 controls myeloid lineage development and function publication-title: PLoS Biol – volume: 127 start-page: 2381 year: 2007 end-page: 2390 ident: bib24 article-title: Langerhans cells and lymph node dendritic cells express the tight junction component claudin-1 publication-title: J Invest Dermatol – volume: 14 start-page: 216 year: 2003 end-page: 221 ident: bib23 article-title: Immunomodulation during sublingual therapy in allergic children publication-title: Pediatr Allergy Immunol – volume: 105 start-page: 385 year: 2000 end-page: 390 ident: bib2 article-title: Survey of patients after discontinuing venom immunotherapy publication-title: J Allergy Clin Immunol – reference: SLC16A4 gene function. Available at: – volume: 8 start-page: R3 year: 2007 ident: bib17 article-title: GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists publication-title: Genome Biol – reference: COMMD8 gene function. Available at: – volume: 36 start-page: 480 year: 2008 end-page: 484 ident: bib14 article-title: KEGG for linking genomes to life and the environment publication-title: Nucleic Acids Res – volume: 115 start-page: 1063 year: 2005 end-page: 1067 ident: bib20 article-title: Increased expression of osteopontin is associated with long-term bee venom immunotherapy publication-title: J Allergy Clin Immunol – volume: 37 start-page: 317 year: 2009 end-page: 322 ident: bib16 article-title: GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information publication-title: Nucleic Acids Res – volume: 6 start-page: e24 year: 2009 ident: bib22 article-title: Survival-related profile, pathways, and transcription factors in ovarian cancer publication-title: PLoS Med – volume: 125 start-page: 279 year: 2001 end-page: 284 ident: bib12 article-title: Controlling the false discovery rate in behavior genetics research publication-title: Behav Brain Res – volume: 108 start-page: 1027 year: 2001 end-page: 1032 ident: bib5 article-title: Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses publication-title: J Allergy Clin Immunol – volume: 29 start-page: 1165 year: 2001 end-page: 1188 ident: bib11 article-title: The control of the false discovery rate in multiple testing under dependency publication-title: Ann Stat – volume: 283 start-page: 14257 year: 2008 end-page: 14268 ident: bib26 article-title: A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein publication-title: J Biol Chem – volume: 60 start-page: 1459 year: 2005 end-page: 1470 ident: bib3 article-title: Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice publication-title: Allergy – volume: 118 start-page: 496 year: 2006 end-page: 503 ident: bib19 article-title: Immune cell transcriptome datasets reveal novel leukocyte subset-specific genes and genes associated with allergic processes publication-title: J Allergy Clin Immunol – reference: . – volume: 3 start-page: 331 year: 1966 end-page: 333 ident: bib10 article-title: Diagnosis and treatment of insect sensitivity publication-title: J Asthma Res – volume: 108 start-page: 1027 year: 2001 ident: 10.1016/j.jaci.2010.01.021_bib5 article-title: Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2001.119154 – volume: 8 start-page: R3 year: 2007 ident: 10.1016/j.jaci.2010.01.021_bib17 article-title: GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists publication-title: Genome Biol doi: 10.1186/gb-2007-8-1-r3 – volume: 118 start-page: 496 year: 2006 ident: 10.1016/j.jaci.2010.01.021_bib19 article-title: Immune cell transcriptome datasets reveal novel leukocyte subset-specific genes and genes associated with allergic processes publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2006.04.040 – volume: 105 start-page: 385 year: 2000 ident: 10.1016/j.jaci.2010.01.021_bib2 article-title: Survey of patients after discontinuing venom immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/S0091-6749(00)90092-7 – volume: 6 start-page: e316 year: 2008 ident: 10.1016/j.jaci.2010.01.021_bib13 article-title: Twist-2 controls myeloid lineage development and function publication-title: PLoS Biol doi: 10.1371/journal.pbio.0060316 – volume: 6 start-page: e24 year: 2009 ident: 10.1016/j.jaci.2010.01.021_bib22 article-title: Survival-related profile, pathways, and transcription factors in ovarian cancer publication-title: PLoS Med doi: 10.1371/journal.pmed.1000024 – volume: 99 start-page: 153 year: 1997 ident: 10.1016/j.jaci.2010.01.021_bib6 article-title: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis publication-title: J Allergy Clin Immunol doi: 10.1016/S0091-6749(97)70314-2 – volume: 36 start-page: 480 year: 2008 ident: 10.1016/j.jaci.2010.01.021_bib14 article-title: KEGG for linking genomes to life and the environment publication-title: Nucleic Acids Res doi: 10.1093/nar/gkm882 – ident: 10.1016/j.jaci.2010.01.021_bib25 – volume: 3 start-page: 331 year: 1966 ident: 10.1016/j.jaci.2010.01.021_bib10 article-title: Diagnosis and treatment of insect sensitivity publication-title: J Asthma Res doi: 10.3109/02770906609106941 – volume: 120 start-page: 2 year: 2007 ident: 10.1016/j.jaci.2010.01.021_bib7 article-title: Risk assessment in anaphylaxis: current and future approaches publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2007.05.001 – ident: 10.1016/j.jaci.2010.01.021_bib27 – volume: 34 start-page: 354 year: 2006 ident: 10.1016/j.jaci.2010.01.021_bib15 article-title: From genomics to chemical genomics: new developments in KEGG publication-title: Nucleic Acids Res doi: 10.1093/nar/gkj102 – volume: 115 start-page: 1063 year: 2005 ident: 10.1016/j.jaci.2010.01.021_bib20 article-title: Increased expression of osteopontin is associated with long-term bee venom immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.01.055 – volume: 283 start-page: 14257 year: 2008 ident: 10.1016/j.jaci.2010.01.021_bib26 article-title: A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein publication-title: J Biol Chem doi: 10.1074/jbc.M801531200 – volume: 127 start-page: 2381 year: 2007 ident: 10.1016/j.jaci.2010.01.021_bib24 article-title: Langerhans cells and lymph node dendritic cells express the tight junction component claudin-1 publication-title: J Invest Dermatol doi: 10.1038/sj.jid.5700882 – volume: 29 start-page: 1165 year: 2001 ident: 10.1016/j.jaci.2010.01.021_bib11 article-title: The control of the false discovery rate in multiple testing under dependency publication-title: Ann Stat doi: 10.1214/aos/1013699998 – volume: 125 start-page: 279 year: 2001 ident: 10.1016/j.jaci.2010.01.021_bib12 article-title: Controlling the false discovery rate in behavior genetics research publication-title: Behav Brain Res doi: 10.1016/S0166-4328(01)00297-2 – volume: 60 start-page: 1459 year: 2005 ident: 10.1016/j.jaci.2010.01.021_bib3 article-title: Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice publication-title: Allergy doi: 10.1111/j.1398-9995.2005.00960.x – volume: 61 start-page: 796 year: 2006 ident: 10.1016/j.jaci.2010.01.021_bib18 article-title: Mechanisms of allergen specific immunotherapy—T-cell tolerance and more publication-title: Allergy doi: 10.1111/j.1398-9995.2006.01175.x – volume: 67 start-page: 2541 year: 2003 ident: 10.1016/j.jaci.2010.01.021_bib1 article-title: Stinging insect allergy publication-title: Am Fam Physician – volume: 86 start-page: 211 year: 2008 ident: 10.1016/j.jaci.2010.01.021_bib8 article-title: Application of the naïve Bayesian classifier to optimize treatment decisions publication-title: Radiother Oncol doi: 10.1016/j.radonc.2007.10.019 – volume: 14 start-page: 216 year: 2003 ident: 10.1016/j.jaci.2010.01.021_bib23 article-title: Immunomodulation during sublingual therapy in allergic children publication-title: Pediatr Allergy Immunol doi: 10.1034/j.1399-3038.2003.00025.x – volume: 23 start-page: 89 year: 2001 ident: 10.1016/j.jaci.2010.01.021_bib9 article-title: Machine learning for medical diagnosis: history, state of the art and perspective publication-title: Artif Intell Med doi: 10.1016/S0933-3657(01)00077-X – volume: 101 start-page: 606 year: 1998 ident: 10.1016/j.jaci.2010.01.021_bib4 article-title: Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients publication-title: J Allergy Clin Immunol doi: 10.1016/S0091-6749(98)70167-8 – volume: 37 start-page: 317 year: 2009 ident: 10.1016/j.jaci.2010.01.021_bib16 article-title: GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information publication-title: Nucleic Acids Res doi: 10.1093/nar/gkp416 – volume: 53 start-page: 944 year: 2004 ident: 10.1016/j.jaci.2010.01.021_bib21 article-title: A microarray screen for novel candidate genes in coeliac disease pathogenesis publication-title: Gut doi: 10.1136/gut.2003.018374 |
| SSID | ssj0009389 |
| Score | 2.0646026 |
| Snippet | Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a resystemic reaction... Background Venom immunotherapy (VIT) enables longtime prevention of insect venom allergy in the majority of patients. However, in some, the risk of a... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1092 |
| SubjectTerms | Adult Aged Allergies Allergy and Immunology Animals Arthropod Venoms - administration & dosage Arthropod Venoms - immunology Bee Venoms - administration & dosage Bee Venoms - immunology Bees - immunology Biological and medical sciences Desensitization, Immunologic Female Fundamental and applied biological sciences. Psychology Fundamental immunology Gene expression Gene Expression Profiling - methods Humans Hypersensitivity, Immediate - etiology Hypersensitivity, Immediate - immunology Hypersensitivity, Immediate - therapy Immunopathology Immunotherapy Immunotherapy - methods Insect Bites and Stings - immunology Insect venom allergy Male Medical sciences microarray assessment Middle Aged prediction of treatment efficacy Proteins Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Treatment Outcome Venom venom immunotherapy Wasp Venoms - administration & dosage Wasp Venoms - immunology Wasps - immunology |
| Title | Gene expression analysis in predicting the effectiveness of insect venom immunotherapy |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0091674910001156 https://www.clinicalkey.es/playcontent/1-s2.0-S0091674910001156 https://dx.doi.org/10.1016/j.jaci.2010.01.021 https://www.ncbi.nlm.nih.gov/pubmed/20334904 https://www.proquest.com/docview/1550191620 https://www.proquest.com/docview/733301253 https://www.proquest.com/docview/754868675 |
| Volume | 125 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1faxQxEB9KBRFE_O9qLXnwTdYmm2Q3eSzFcirtk8W-hSSbyBa7d7hX0Bc_i5_FT-bkNntH0Z7g62yGJLOTyQz5zQzAK28F9ZH5UqJ7XAptWakVHve6spVyPiq7at92clrPzsT7c3m-A0dTLkyCVWbbP9r0lbXOlIMszYNF16UcX50g9JqNfk0quy1Ek7T8zY8NzENzNbrAmpVpdE6cGTFeF9Z3Gd6VSneymy6nuws7oMji2OviZmd0dSkd34d72Zskh-OCH8BO6B_C7ZP8Xv4IPqWq0iR8y2jXnthcg4R0PUFimxJC-s8EvUAyIjuy8SPz-Otn1w9IIUiZX5IuJZLkdK3vj-Hs-O3Ho1mZWymUXmq5LFW0sqWqbZSMUdVeNkx6bisMVmjrqWu0i0FxUQXXBioiumHMhiC5jBqDHM2fwG4_78MzIDyoqFz0DGNywZx1rm2l9dErV4c2iALYJEPjc53x1O7ii5kAZRcmyd0kuRvKDMq9gNdrnsVYZWPraD79GjPlj6LFM3gJbOVq_sYVhnxoB8PMUBlq_lCsAuSa85pu_nPG_Wt6s95ahXFuKkRYwN6kSGazCowZMYiuK1oAWX_GQ59ecmwf5leDaThHw1xJvmUIhqK1wnCwgKejim6mp5wLTcXz_9zXC7gzYSgo24Pd5der8BJds6XbX529fbh1-O7D7PQ32LQ5Ag |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB6VIgESQvw3UIoP3FCoHceJfUQV1QLdnlrRm2U7NkoF2VWzleDCs_AsPBnjjbOrCrpIXCe2bE9mxjPyNzMAr5wpqQvM5QLd47xUhuVKorpXhSmkdUGaZfu26XE1OS0_nImzLTgYc2EirDLZ_sGmL611ouwnbu7P2zbm-KoIoVds8GuqG3CzRPWNbQze_FjjPBSXgw-sWB6Hp8yZAeR1blyb8F2xdie77na6Ozc98iwMzS6u90aXt9LhfbiX3EnydtjxA9jy3UO4NU0P5o_gUywrTfy3BHftiElFSEjbESQ2MSOk-0zQDSQDtCNZPzILv362XY8UgpTZV9LGTJKUr_X9MZwevjs5mOSpl0LuhBKLXAYjGiqbWooQZOVEzYTjpsBohTaO2lrZ4CUvC28bT8uAfhgz3gsugsIoR_EnsN3NOr8DhHsZpA2OYVBeMmusbRphXHDSVr7xZQZs5KF2qdB47HfxRY-IsnMd-a4j3zVlGvmewevVnPlQZmPjaD7-Gj0mkKLJ03gLbJxV_22W75PW9prpvtBU_yFZGYjVzCvC-c8V967IzepoBQa6sRJhBrujIOn1LjBoxCi6KmgGZPUZtT4-5ZjOzy57XXOOlrkQfMMQjEUrifFgBk8HEV0vTzkvFS2f_ee5XsLtycn0SB-9P_74HO6MgArKdmF7cXHpX6CftrB7Sz38Dag6OpA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gene+expression+analysis+in+predicting+the+effectiveness+of+insect+venom+immunotherapy&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Niedoszytko%2C+Marek&rft.au=Bruinenberg%2C+Marcel&rft.au=de+Monchy%2C+Jan&rft.au=Wijmenga%2C+Cisca&rft.date=2010-05-01&rft.pub=Elsevier+Limited&rft.issn=0091-6749&rft.eissn=1097-6825&rft.volume=125&rft.issue=5&rft.spage=1092&rft_id=info:doi/10.1016%2Fj.jaci.2010.01.021&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=3389957141 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00916749%2FS0091674910X00070%2Fcov150h.gif |